More importantly, combined treatment with Prdm1 overexpression and PD-1 mAb further impaired tumor proliferation and prolonged survival time compared with that in Prdm1 overexpression or PD-1 mAb treatment alone (Fig. 6a, c, e, f). This evidence concerns the gene PRDM1 and neoplasm.